+ Filter
Loading...
ERBB2 & CD3
Loading...Anti-ERBB2 & CD3 Products
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
- Anti-ERBB2 immunotoxin 4D5 (scFv)-DT (AGTO-G022D)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Derivation: Chimeric (Human/Mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: IF, IP, Neut, FuncS, ELISA, FC, WB
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FuncS, IF, Neut, ELISA, FC, IP, WB
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: ELISA, WB, FC
-
- Species Reactivity: Human
- Type: Human IgG
- Application: WB
- Rat Anti-CD3 Recombinant Antibody (clone 17A2) (MOB-0202MC)
-
- Species Reactivity: Mouse
- Type: Rat IgG2b, κ
- Application: FC, IHC, IP, Activ, CMCD, Depletion
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA, WB, FuncS
- Anti-Human CD3 Recombinant Antibody Fab Fragment (TAB-071LC-F(E))
-
- Derivation: Chimeric (mouse/human)
- Type: Chimeric antibody (mouse/human)
- Application: ELISA
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA, WB, FuncS
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Fab fragment
- Application: ELISA
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL2
- Host: Humanized from Mouse
- Cytokine 1 Species: Human
- Molecule Class: scFv‑Fc‑IL2
- Anti-ERBB2 immunotoxin 4D5 (scFv)-PE (AGTO-G022E)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Species Reactivity: Human
- Type: Llama VHH
- Application: IHC, FC, CA, FuncS
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel (AGTO-G022G)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA (AGTO-G022R)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap (AGTO-G022S)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Scaffold Name: Z-domain of protein A
- Target: Her2
- Species Reactivity: Human
- Derivation: Phage display
-
- Scaffold Name: 2-Helix small protein
- Target: HER2
- Species Reactivity: Human
- Derivation: Phage display
- Mouse Anti-CD3 Recombinant Antibody; Fab Fragment (TAB-070LC-F(E)) (TAB-070LC-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Llama VHH
- Application: ELISA
- Anti-HER2-MT-vc-MMAE ADC (ADC-257CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-253CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-DBCO-MMAF ADC (ADC-310CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-254CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-DBCO-MMAF ADC (ADC-311CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MP(T-vc)-MMAE ADC (ADC-255CL)
-
- Target: HER2
- Linker: MP(T-VC)
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino) phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MC-vc-PABC-MMAE ADC (ADC-256CL)
-
- Target: HER2
- Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: (S,E)-N-(4-(aminomethyl)benzylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-SMCC-DM1 ADC (ADC-001LZY)
-
- Target: HER2
- Linker: SMCC (N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-MCC-DM1 ADC (ADC-174LZY)
-
- Target: Her2
- Linker: MCC (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-mc-vc-PABC-MMAE ADC (ADC-175LZY)
-
- Target: Her2
- Linker: mc-VC-PABC (maleimidocaproyl valine-citrulline-p-aminobenzyl carbamoyl)
- Drug: MMAE (monomethyl auristatin E)
- Anti-Her2-saporin 6 A157C ADC (ADC-164LZY)
-
- Target: Her2
- Linker: aminooxy-maleimide linker
- Drug: saporin 6 A157C
- Anti-HER2 (trastuzumab)-mcc-DM1 ADC (ADC-129LCT)
-
- Target: HER2
- Linker: mcc (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- thio-Anti-HER2 (trastuzumab)-mpeo-DM1 ADC (ADC-130LCT)
-
- Target: HER2
- Linker: mpeo
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-MT-vc-MMAE ADC (ADC-258CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-SPP-DM1 ADC (ADC-132LZY)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-HER2-DUBA-Duocarmycins ADC (ADC-069LZY)
-
- Target: HER2
- Linker: DUBA (DUocarmycinhydroxyBenzamide-Azaindole
linker) ("mc"-VC-PABC-CM) - Drug: Duocarmycins
- Anti-HER2-DBCO-MMAF ADC (ADC-307CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-[14C]-SMCC-DM1 ADC (ADC-150LZY)
-
- Target: HER2
- Linker: [14C]-SMCC
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-HER2-vc-MMAE ADC (ADC-081LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: MMAE(monomethyl auristatin E)
- Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] (IAB-B008(A))
-
- Species Reactivity: human
- Type: scFv-(D-Arg)9
- Application: IF, FC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [+36 GFP] (IAB-B008(G))
-
- Species Reactivity: human
- Type: scFv-(+36GFP)
- Application: WB, ICC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [Tat] (IAB-B008(T))
-
- Species Reactivity: human
- Type: scFv-Tat
- Application: ICC, Neut, FuncS
- Anti-HER2-DBCO-MMAF ADC (ADC-309CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (trastuzumab)-mc-c-term-Dol15 ADC (ADC-128LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: dolastatin 15 derivatives (Dol15)
- Anti-HER2-vandetanib ADC (ADC-068LZY)
-
- Target: HER2
- Drug: vandetanib
- Anti-HER2-DOX ADC (ADC-131LZY)
-
- Target: HER2
- Linker: thiomaleamicacids-p-aminobenzyloxycarbonyl
- Drug: doxorubicin
- Anti-HER2-vc-Duostatin-3 ADC (ADC-087LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: Duostatin-3
- Anti-HER2-DBCO-MMAF ADC (ADC-308CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (Trastuzumab)-CC-MMAD ADC (ADC-126LCT)
-
- Target: HER2
- Linker: CC
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2 (Trastuzumab)-mc-MMAD ADC (ADC-127LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAD (monomethyl auristatin D)
-
- Target: HER2
- Linker: vc (valine-citrulline)
- Drug: Duocarmycins
-
- Target: HER2
- Linker: thioether SMCC linker
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-SPDP-DM1 ADC (ADC-134LCT)
-
- Target: HER2
- Linker: SPDP ( N-succinimidyl 3-(2-pyridyldithio)propionate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-SPP-DM1 ADC (ADC-135LCT)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-SSNPP-DM3 ADC (ADC-136LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM3
- Anti-HER2 (trastuzumab)-SSNPP-DM4 ADC (ADC-137LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Anti-HER2 (trastuzumab)-auristatin ADC (ADC-138LCT)
-
- Target: HER2
- Linker: The linker contains two ethylene glycol moieties modified with a terminal alkoxy-amine group to improve solubility and minimize export of the more hydrophilic derivatized analogs by drug pumps
- Drug: auristatin
- Anti-HER2 Fab (trastuzumab)-Porphyrin ADC (ADC-139LCT)
-
- Target: HER2
- Drug: Porphyrin
- Anti-HER2 Fab (trastuzumab)-PEG-porphyrin ADC (ADC-140LCT)
-
- Target: HER2
- Linker: PEG
- Drug: porphyrin
- Anti-Her-2 receptor-Phor18 molecules ADC (ADC-132CL)
-
- Target: Her-2 receptor
- Linker: 2, 4 or 6 Phor18 molecules
- Anti-Her2-ALKYNE-MMAF ADC (ADC-209CL)
-
- Target: Her2
- Linker: ALKYNE
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-Gly5-modified DM1 ADC (ADC-147CL)
-
- Target: HER2
- Drug: Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-MODO ADC (ADC-264CL)
-
- Target: HER2
- Drug: MODO (monomethyldolastatin)
- Anti-Her2-VCP-cyclooctyne-MMAF ADC (ADC-210CL)
-
- Target: Her2
- Linker: valine-citruline-p-amino-benzoyl-carbonate (VCP)-cyclooctyne
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-vcPAB-MMAE ADC (ADC-148CL)
-
- Target: HER2
- Linker: VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-MT-vc-MMAE ADC (ADC-248CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-DBCO-MMAF ADC (ADC-295CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-249CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2 (clone hu4D5Fabv8)-MC-vc-PAB-MMAF ADC (ADC-183CL)
-
- Target: HER2
- Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-296CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-250CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-DBCO-MMAF ADC (ADC-297CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-MC-MMAF ADC (ADC-184CL)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-251CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-DBCO-MMAF ADC (ADC-298CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-BMPEO-DM1 ADC (ADC-185CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-DBCO-MMAF ADC (ADC-299CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-252CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-BMPEO-DM1 ADC (ADC-186CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
-
- Target: HER2
- Linker: hydroxyl amino PEG linker
- Drug: MMAD (monomethyl auristatin D)
-
- Target: HER2
- Linker: MC-PEG8
- Drug: Dol10 (Thiol Dol10)
- Anti-HER2-DBM-MMAF ADC (ADC-105LZY)
-
- Target: HER2
- Linker: DBM(dibromomaleimide)
- Drug: MMAF(monomethyl auristatin F)
- Anti-Her2-vc-[14C]MMAE ADC (ADC-221LZY)
-
- Target: Her2
- Linker: VC(valine-citrulline)
- Drug: [14C]MMAE(14C-labeled monomethyl auristatin E)
-
- Target: HER2
- Linker: AO-Mc-PEG8
- Drug: Dol10 (Thiol Dol10)
- Anti-HER2-mc-MMAF ADC (ADC-107LZY)
-
- Target: HER2
- Linker: mc(maleimidocaproyl)
- Drug: MMAF(monomethyl auristatin F)
- Anti-HER2 (Trastuzumab)-MC-MMAE (Thiol MMAE) ADC (ADC-103LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-NGMs-MMAE ADC (ADC-035LZY)
-
- Target: HER2
- Linker: NGMs(next generation maleimides)
- Drug: MMAE (monomethyl auristatin E)
- Anti-HER2 (Trastuzumab)-AO-MC-MMAE (Glyco MMAE) ADC (ADC-104LCT)
-
- Target: HER2
- Linker: AO-Mc-
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-DBCO-MMAF ADC (ADC-300CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-Amberstatin (AS269) ADC (ADC-109LZY)
-
- Target: HER2
- Linker: non-natural amino acids (Ambrx' technology)
- Drug: Amberstatin (AS269)
- Anti-HER2 (trastuzumab) Fab-bisAlk-vc-MMAE ADC (ADC-122LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (trastuzumab)-bisAlk-vc-MMAE ADC (ADC-123LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains.


Bladder Cancer
Non-small Cell Lung Cancer
ErbB Signaling Pathway
